Featured XIENCE Short DAPT Trials

“Two really exciting studies but much more important is what we're doing for the patients.”


“We really are in a dilemma in balancing the risk of ischemic events that are associated with PCI...compared to their bleeding risk...with prolonged DAPT” 


Abbott has established the XIENCE Short DAPT program of clinical trials, which focuses on high risk bleeding patients. Shortening DAPT (Dual AntiPlatelet Therapy) duration may be particularly important for patients at higher risk of bleeding, e.g., older patients, patients taking anticoagulants, and patients with anemia or renal disease.

The studies in the XIENCE Short DAPT program are:

Dr. Mehran is global principal investigator of the XIENCE 90 trial. The principal investigator of the XIENCE 28 study is Marco Valgimigli, MD.

Currently physicians have no clear guidance when weighing their patients’ needs and risk factors—their need for DAPT to reduce ischemic complications after percutaneous coronary intervention (PCI) and, for many patients, their bleeding risk while on prolonged DAPT.

“We have a lot of patients in whom DAPT cannot be longer than 1 [month] and we need to provide some answers to them.” 


Find out more about both the XIENCE 90 and XIENCE 28 Global trials. You may also sign up to receive updates on the latest XIENCE study results as they become available.

Get the latest data

Sign up to receive the latest about XIENCE study results as they become available.

Sign up

† Bench test data shows that XIENCE Sierra performed better in crossability and was not statistically different in trackability and pushability compared to Resolute Onyx and SYNERGY stents. Bench test results may not necessarily be indicative of clinical performance. Test performed by and data on file at Abbott. Testing performed on XIENCE Sierra Everolimus Eluting Coronary Stent System (3.0 x 18 mm) n=5, SYNERGY Stent System (3.0 x 20 mm) n=5, Resolute Onyx Stent System (3.0 x 18 mm) n=5. Catheter performance crossability test measures average force to cross a challenging lesion model.

‡ Increased maximum expansion compared to other XIENCE Everolimus Eluting Coronary Stent System.

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?

Are you a healthcare professional in the
U.S. or outside of the U.S.?